Kristin Haag, PA
Physician Assistant · Shelbyville, ILNPI 1790267524
Payments from drug & device makers
Across 305 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$693
- AbbVie$467
- Pfizer$461
- Novartis$457
- Lilly USA, LLC$362
- AstraZeneca$297
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,740100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $693 |
| AbbVie | 26 | $467 |
| Pfizer | 32 | $461 |
| Novartis | 27 | $457 |
| Lilly USA, LLC | 21 | $362 |
| AstraZeneca | 18 | $297 |
| Boehringer Ingelheim | 14 | $255 |
| Johnson & Johnson | 19 | $222 |
| Amgen | 13 | $207 |
| GSK | 10 | $205 |
| Abbott | 9 | $166 |
| Neurocrine Biosciences, Inc. | 6 | $161 |
| Merck | 10 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $112 |
| Mylan Specialty L.p. | 6 | $89 |
| Exact Sciences | 4 | $80 |
| Bayer | 3 | $53 |
| Astellas Pharma US Inc | 4 | $53 |
| Amarin Pharma, Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$4,740 in reported general payments places this provider in the 90th percentile of 3,912 physician assistant providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 144 | $148,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 156 | $98,775 |
| IngrezzaValbenazine Tosylate | 12 | $98,362 |
| LinzessLinaclotide | 115 | $77,798 |
| OzempicSemaglutide | 59 | $75,117 |
| JanuviaSitagliptin Phosphate | 73 | $69,754 |
| TradjentaLinagliptin | 61 | $52,491 |
| XareltoRivaroxaban | 53 | $46,000 |
| FarxigaDapagliflozin Propanediol | 33 | $32,254 |
| EliquisApixaban | 32 | $32,120 |
| RybelsusSemaglutide | 32 | $29,215 |
| ProliaDenosumab | 14 | $25,629 |
| TrulicityDulaglutide | 19 | $21,669 |
| MounjaroTirzepatide | 19 | $18,435 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $16,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $255 | $201,369205 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $205 | $104,651171 claims |
| Novo NordiskOzempic, Rybelsus | $693 | $104,33291 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $161 | $98,36212 claims |
| AbbVieLinzess | $467 | $77,798115 claims |
| MerckJanuvia, Belsomra | $138 | $75,33785 claims |
| Johnson & JohnsonXarelto | $222 | $46,00053 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $362 | $40,10438 claims |
| AstraZenecaFarxiga | $297 | $32,25433 claims |
| PfizerEliquis | $461 | $32,12032 claims |
| AmgenProlia | $207 | $25,62914 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $6,60815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,912 physician assistant providers in Illinois.
Other physician assistant in Shelbyville
- Andrew MastroChicago$419K
- Christopher AricoSkokie$407K
- Karlijn BurridgeWestmont$144K
- Ian MackeySkokie$135K
- Stephanie TraceyItasca$122K
- Olabimpe PhilipsAddison$103K
- Renata BlockChicago$103K
- Margaret RomanoChicago$82K
- Christina StarksChicago$77K
- Darrel CutlerHerrin$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.